Country Us was EyePoint’s largest region in fiscal 2025, bringing in $29.98M of $31.37M (96%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | — | — | — | — | ||||||||||||
| Country Us | $40.48M | $45.27M | $42.05M | $29.98M | ||||||||||||
| U.S | — | — | — | — | ||||||||||||
| China | $823.00K | $648.00K | $1.12M | $1.29M | ||||||||||||
| United Kingdom | $100.00K | $100.00K | $100.00K | $100.00K | ||||||||||||
| U.K | — | — | — | — | ||||||||||||
| Total | $41.40M | $46.02M | $43.27M | $31.37M |
EyePoint brought in $31.37M from its three regions in fiscal 2025, the year ended December 31, 2025. That was down 27.5% from $43.27M in fiscal 2024. Country Us was the largest at $29.98M (95.6%), ahead of China at $1.29M (4.1%) and United Kingdom at $100.00K (0.3%).
Compared with fiscal 2024, China grew 14.9% to $1.29M, while Country Us fell 28.7% to $29.98M. From fiscal 2022 to 2025, combined revenue from these regions fell from $41.40M to $31.37M, a compound annual decline of 8.8%. Country Us' share of the total fell from 97.8% to 95.6%.
License & Collaboration Agreement was EyePoint’s largest product and service line in fiscal 2025, bringing in $16.73M of $31.37M (53%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Yutiq | $28.33M | — | — | — | |||||||
| License & Collaboration Agreement | $362.00K | $30.80M | $38.50M | $16.73M | |||||||
| Dexycu | $11.58M | — | — | — | |||||||
| Product Sales, Net | — | $14.23M | $3.16M | $1.60M | |||||||
| Royalty Income | $1.14M | $989.00K | $1.61M | $13.04M | |||||||
| Collaborative Research & Development | — | — | — | — | |||||||
| Total | $41.40M | $46.02M | $43.27M | $31.37M |
EyePoint brought in $31.37M from its three product and service lines in fiscal 2025, the year ended December 31, 2025. That was down 27.5% from $43.27M in fiscal 2024. License & Collaboration Agreement was the largest at $16.73M (53.3%), ahead of Royalty Income at $13.04M (41.6%) and Product Sales, Net at $1.60M (5.1%).
Compared with fiscal 2024, Royalty Income grew fastest, up 708.5% to $13.04M, while License & Collaboration Agreement fell the most, down 56.5% to $16.73M.
EyePoint began breaking out Product Sales, Net in fiscal 2023, when it brought in $14.23M. EyePoint stopped reporting Yutiq ($28.33M in fiscal 2022) and Dexycu ($11.58M in fiscal 2022) as separate lines.
Product Rights Agreement & The Supply Agreement was EyePoint’s largest revenue line in fiscal 2025, bringing in $16.60M of $31.30M (53%).
| Collaborative Arrangement and Arrangement Other than Collaborative | FY 2025 |
|---|---|
| Product Rights Agreement & The Supply Agreement | $16.60M |
| Swk | $12.70M |
| Ocumension Therapeutics | $1.40M |
| Ani Pharmaceuticals, Inc | $600.00K |
| Total | $31.30M |
EyePoint brought in $31.30M from its four revenue lines in fiscal 2025, the year ended December 31, 2025. Product Rights Agreement & The Supply Agreement was the largest at $16.60M (53.0%), ahead of Swk at $12.70M (40.6%) and Ocumension Therapeutics at $1.40M (4.5%). The remaining revenue line, Ani Pharmaceuticals, Inc, brought in $600.00K.
EyePoint (EYPT) reports its revenue by geography, by product and service and by collaborative arrangement and arrangement other than collaborative. In fiscal 2025, Country Us was its largest region, bringing in $29.98M (95.6% of the total), followed by China at $1.29M (4.1%).
Country Us was EyePoint's largest region in fiscal 2025, bringing in $29.98M, or 95.6% of the $31.37M total across its three regions.
License & Collaboration Agreement was EyePoint's largest product and service line in fiscal 2025, bringing in $16.73M, or 53.3% of the $31.37M total across its three product and service lines.
Product Rights Agreement & The Supply Agreement was EyePoint's largest revenue line in fiscal 2025, bringing in $16.60M, or 53.0% of the $31.30M total across its four revenue lines.
China grew faster than Country Us in fiscal 2025, up 14.9% from $1.12M to $1.29M. Country Us fell 28.7% to $29.98M.
Every figure comes from EyePoint's annual financial filings, as reported. Each line keeps the name EyePoint gives it, and years follow its fiscal calendar.
EyePoint's revenue by geography goes back to fiscal 2010, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.